Kiniksa Pharmaceuticals International, plc (KNSA): Depreciation & Amortization
$1.55M
Year ended 2025-12-31
$1.68M
Trailing 12 months to 2026-03-31
-13.5%
3-year compound annual growth
-8.4%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.55M | -8.3% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $1.70M | -27.6% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $2.34M | -2.5% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $2.40M | +2.0% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $2.35M | -2.1% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $2.40M | +16.3% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $2.07M | n/a | 2022-02-24, From 2019-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $1.55M | -8.3% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $35.00M | -2.8% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $91.56M | +13.9% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $91.02M | +15.5% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $95.80M | -11.9% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $59.0K | -13.2% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $91.63M | -6.7% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $1.15M | +44.5% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $15.27M | +12.1% |
Compare KNSA, RARE, SUPN, PCRX side by side · Screen every company in Pharmaceutical Preparations ↗